EVAX
Evaxion Biotech A/S
NASDAQ · Healthcare · Biotechnology · DK
$3.12
+1.30%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.9x
Market Cap
$26.02M
MomentumView details →
1D Return
+1.30%
YTD Return
−35.64%
RSI (14)
47.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.9x
Market Cap
$26.02M
RSI (14)
47.0
MomentumView details →
1D Return
+1.30%
YTD Return
−35.64%
SummaryUpdated Jun 1, 2026
Evaxion Biotech A/S (NASDAQ:EVAX) is a Danish clinical-stage biotechnology company founded in 2008 and headquartered in Hørsholm, Denmark. The company went public on NASDAQ in February 2021. Evaxion specializes in developing artificial intelligence-powered immunotherapies targeting cancers, bacterial diseases, and viral infections. The company has evolved from a traditional biotech firm into an AI-driven immunotherapy platform company, leveraging proprietary machine learning algorithms to identify and develop novel vaccine candidates across multiple therapeutic areas.
Similar companies
Latest newsMore news →
Evaxion A/S announced it will release its second quarter 2026 financial results and provide a business update on August 20, 2026.22d agoNyxoah SA's Genio hypoglossal nerve stimulation therapy won the Prix Galien UK 2026 Award for Best Medical Technology at a ceremony in London.81d agoEvaxion received the 2026 Prix Galien UK Award for Best digital health solution for its AI-Immunology platform.85d ago